Jason Carr/iStock via Getty Images Introduction Occidental Petroleum Corporation ( OXY ) has seen its stock surge on the back of the Iran situation, like many names in the oil & gas industry, since I last rated it a Buy back in September. In all, the stock posted a total return of 24.67% since, vastly outpacing the S&P 500 ( SP500 ) return of 8.98% during that time. With the recent earnings as wel...
Jason Carr/iStock via Getty Images Introduction Occidental Petroleum Corporation ( OXY ) has seen its stock surge on the back of the Iran situation, like many names in the oil & gas industry, since I last rated it a Buy back in September. In all, the stock posted a total return of 24.67% since, vastly outpacing the S&P 500 ( SP500 ) return of 8.98% during that time. With the recent earnings as well as the tensions easing in the Middle East, I want to dive into what the setup looks like right now. Q1 Review Occidental Petroleum posted a mixed set of earnings as revenue came out to $5.23B, a miss of $440MM and an 8.4% Y/Y decrease. On the bottom line, OXY posted a Non-GAAP EPS of $1.06, a massive beat of 47 cents. So, how come the bottom line rose so much? Well, that’s based on 3 distinct factors, with the first being the midstream and market adj. income surging to $591MM from $237MM in Q4, thanks to crude margin timing benefits and gas transportation capacity optimization. The effective tax rate also dropped to 26% from 35% over the previous quarter, contributing roughly 10 to 12 cents of EPS upside. Permian production also beat expectations at 787 Mboed, supporting the realized oil price strength. Thanks to the proceeds of the OxyChem sale , that’s why total net income reached $3.2B for the quarter. Though one thing that majorly surprised me has been the reported negative free cash flow that stood at -$112MM in the quarter compared to $466MM last year, which is quite astonishing when considering the differences in crude prices. Management has attributed this to a $1.8B working capital drag, sharply higher trade receivables driven by the late-quarter spike in prices, and a seasonal Q1 cash demand. On a pre-working capital basis, FCF was a healthy $1.7B. But the consensus full-year FCF estimate is at around $7B, meaning that Oxy requires the working capital reversal to come through cleanly in the remainder of the year. If I’m being honest, the financial performance du...
Lucid Group (NASDAQ:LCID) saw its Morgan Stanley price target cut in half to $5 from $10 on May 6, with the firm keeping its Underweight rating. The cut follows a 29-day stop-sale on the Gravity SUV tied to a supplier quality issue, suspension of full-year guidance, and an unresolved CEO transition. For LCID stock investors, ... Morgan Stanley Slashes Lucid Price Target in Half: Stop-Sale, CEO Hun...
Lucid Group (NASDAQ:LCID) saw its Morgan Stanley price target cut in half to $5 from $10 on May 6, with the firm keeping its Underweight rating. The cut follows a 29-day stop-sale on the Gravity SUV tied to a supplier quality issue, suspension of full-year guidance, and an unresolved CEO transition. For LCID stock investors, ... Morgan Stanley Slashes Lucid Price Target in Half: Stop-Sale, CEO Hunt Spell Deep Trouble
jaanalisette/iStock Editorial via Getty Images Banco Santander ( SAN ) is exploring hedging a portfolio of buy now, pay later loans through the booming market for significant risk transfers, or SRTs, according to a media report on Wednesday. The lender is in talks with investors for an SRT linked to ~€500M ($588M) of loans its digital banking arm made to clients in Germany, Bloomberg News reported...
jaanalisette/iStock Editorial via Getty Images Banco Santander ( SAN ) is exploring hedging a portfolio of buy now, pay later loans through the booming market for significant risk transfers, or SRTs, according to a media report on Wednesday. The lender is in talks with investors for an SRT linked to ~€500M ($588M) of loans its digital banking arm made to clients in Germany, Bloomberg News reported, citing people familiar with the matter. The terms of the potential deal could change as the process continues, they said. Banco Santander ( SAN ) stock rose 4.3% in midday trading. The use of SRTs has surged as European and North American banks seek to shift risks linked to corporate lending amid strong demand from pension managers and hedge funds. Financial institutions are also using the vehicles to manage riskier parts of their balance sheet, such as consumer credit and commercial real estate, Bloomberg noted. While Santander ( SAN ) has been among the most active in issuing SRTs, the potential transaction would be its first tied to buy now, pay later loans, which are often interest-free installment loans that allow consumers to split the payments of purchases. More on Banco Santander Banco Santander, S.A. 2026 Q1 - Results - Earnings Call Presentation Banco Santander, S.A. (SAN) Q1 2026 Earnings Call Transcript Banco Santander, S.A. 2026 Q1 - Results - Earnings Call Presentation Banco Santander Q1 results lifted by disposal gain Santander stock down as bank suspends stock repurchases on pending Webster acquisition
In this article NVO NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. "If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world," said Novo Nordisk CEO Mike Doustdar. "So let's go...
In this article NVO NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. "If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world," said Novo Nordisk CEO Mike Doustdar. "So let's go and see who else basically has assets that are complementary to what we have. And we are quite active with those [business development] talks and acquisitions, and you'll see more of those as well going forward." Novo created the market for GLP-1 weight loss drugs with its weekly shots Ozempic and Wegovy. More recently, the company has faced concerns from analysts about whether Novo's pipeline is robust enough for it to remain a leader in the increasingly competitive obesity drug space. Mike Doustdar, chief executive officer of Novo Nordisk A/S, during an interview in New York, US, on Wednesday, Feb. 11, 2026. Michael Nagle | Bloomberg | Getty Images Rival Eli Lilly has already overtaken Novo in market share for weekly GLP-1 shots, though Novo has taken an early lead in the new category of GLP-1 pills for weight loss. Doustdar said he disagrees with the concerns about Novo's upcoming treatments, arguing the drugmaker has "one of the best pipelines in the industry." He pointed to Novo's CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes will be approved at the end of this year, and an experimental amylin-targeting drug called zenagamtide that Novo has accelerated development of, among other assets. "Of course, there's a lot of things in my pipeline that right now I have the privy to look into and get excited (about) but not have shared it yet with the world," he said. "So I am incredibly excited about our pipeline, and I would just say to the investors who are a little bit skeptical, wait and see." Doustdar spoke to CNBC after the company said its We...
Nuvation Bio ( NUVB ) announced on Wednesday that the U.S. FDA accepted its marketing application aimed at broadening the label for its lung cancer therapy, Ibtrozi. In 2025, the regulator approved the oral ROS1 tyrosine kinase inhibitor for adults with locally advanced or metastatic non-small cell lung cancer whose tumors contain a genetic mutation called ROS1. Submitting a supplemental New Drug ...
Nuvation Bio ( NUVB ) announced on Wednesday that the U.S. FDA accepted its marketing application aimed at broadening the label for its lung cancer therapy, Ibtrozi. In 2025, the regulator approved the oral ROS1 tyrosine kinase inhibitor for adults with locally advanced or metastatic non-small cell lung cancer whose tumors contain a genetic mutation called ROS1. Submitting a supplemental New Drug Application, Nuvation ( NUVB ) seeks its approval for both TKI-naive and TKI-pretreated advanced ROS1-positive NSCLC patients. The FDA accepted the sNDA, assigning January 4, 2027, as the target action date, the company said on Wednesday. The filing, backed by 10 months of additional data from the company's pivotal TRUST-I and TRUST-II studies, which supported the initial approval, makes Nuvation ( NUVB ) compliant with a post-marketing requirement. More on Nuvation Bio Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript Nuvation Bio Inc. (NUVB) Presents at The Citizens Life Sciences Conference 2026 Transcript Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript Nuvation Bio expects gross-to-net to stabilize around 30% as IBTROZI shifts to >50% TKI-naive starts Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo
Foreign industrial stocks have showed strong momentum over the last few months. Nine of the ten names carry a Strong Buy designation, spanning marine shipping, precision machinery, commercial printing, infrastructure, and aviation leasing across markets as varied as Japan, Ireland, Monaco, Hong Kong, and Australia. The geographic and sub-sector diversity here is what makes the list stand out. At t...
Foreign industrial stocks have showed strong momentum over the last few months. Nine of the ten names carry a Strong Buy designation, spanning marine shipping, precision machinery, commercial printing, infrastructure, and aviation leasing across markets as varied as Japan, Ireland, Monaco, Hong Kong, and Australia. The geographic and sub-sector diversity here is what makes the list stand out. At the top, Navios Maritime Partners ( NMM ) leads with a 4.80 Quant score, reflecting continued strength in global dry bulk and tanker markets, while Irish-domiciled Cimpress ( CMPR ) and Japanese trading house Marubeni ( MARUY ) bring very different earnings profiles to back-to-back Strong Buy ratings. Further down, Swedish industrial toolmaker Sandvik ( SDVKY ), Japanese robotics giant Fanuc ( FANUY ), and Australian toll road operator Transurban ( TRAUF ) represent the kind of cash-generative, infrastructure-adjacent businesses that tend to score well on the Quant system's profitability and valuation screens. Rounding out the list, AerCap ( AER ) is the only Buy-rated name, a slight step down in Quant conviction but still a broadly bullish signal for a company sitting at the intersection of aviation recovery and global fleet demand. Here is the list: Navios Maritime Partners L.P. ( NMM ), Quant Rating: 4.80 Cimpress plc ( CMPR ), Quant Rating: 4.71 Marubeni Corporation ( MARUY ), Quant Rating: 4.70 Swire Pacific Limited ( SWRAY ), Quant Rating: 4.68 Sandvik AB (publ) ( SDVKY ), Quant Rating: 4.61 Transurban Group Stapled Securities ( TRAUF ), Quant Rating: 4.57 Fanuc Corporation ( FANUY ), Quant Rating: 4.56 ZTO Express (Cayman) Inc. ( ZTO ), Quant Rating: 4.55 Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. ( OMAB ), Quant Rating: 4.52 AerCap Holdings N.V. ( AER ), Quant Rating: 4.44 More on Navios Maritime, AerCap, etc. Marubeni Corporation 2026 Q4 - Results - Earnings Call Presentation Cimpress plc (CMPR) Q3 2026 Earnings Call Transcript AerCap Holdings N.V. (AER) Q...
Our 24/7 Wall St. price target for Advanced Micro Devices (NASDAQ:AMD) is $398.04, which sits modestly below where shares currently trade after a blistering rally. With AMD changing hands at $416.36 and the model implying roughly -4.4% from here, the recommendation is hold with 90% confidence. Near fair value is the cleanest way to describe ... After Blowout Quarter, This Is AMD’s Price Prediction...
Our 24/7 Wall St. price target for Advanced Micro Devices (NASDAQ:AMD) is $398.04, which sits modestly below where shares currently trade after a blistering rally. With AMD changing hands at $416.36 and the model implying roughly -4.4% from here, the recommendation is hold with 90% confidence. Near fair value is the cleanest way to describe ... After Blowout Quarter, This Is AMD’s Price Prediction For 2026
In this article BRK.B APO Follow your favorite stocks CREATE FREE ACCOUNT Marc Rowan, chief executive officer of Apollo Global Management LLC, speaks during an interview on an episode of Bloomberg Wealth with David Rubenstein in New York, U.S., on Tuesday, April 5, 2022. Jeenah Moon/Bloomberg via Getty Images Jeenah Moon | Bloomberg | Getty Images Apollo Global Management CEO Marc Rowan on Wednesd...
In this article BRK.B APO Follow your favorite stocks CREATE FREE ACCOUNT Marc Rowan, chief executive officer of Apollo Global Management LLC, speaks during an interview on an episode of Bloomberg Wealth with David Rubenstein in New York, U.S., on Tuesday, April 5, 2022. Jeenah Moon/Bloomberg via Getty Images Jeenah Moon | Bloomberg | Getty Images Apollo Global Management CEO Marc Rowan on Wednesday warned investors that he was preparing his giant asset management firm for a potential market downturn and sharply criticized what he called the "egregious" practices of some rival insurers. The current solid economic backdrop — which helped Apollo report a banner quarter, in which the firm reached $1 trillion in assets under management and record fee-related earnings — is masking a growing risk of what he called "out of the box" shocks. "Everything we see in front of us is actually quite strong," Rowan said. But there is "a much greater chance, in our opinion, of out-of-sideline results." Rowan, who co-founded Apollo in 1990 and oversaw its transformation into an alternative asset and insurance giant, said he is now more concerned about outside factors derailing the economy than at any time in his four decades on Wall Street. His comments, which come as the U.S. stock market is trading near record highs, add to concerns voiced by financial executives including JPMorgan Chase CEO Jamie Dimon . Rowan put the odds of an exogenous shock at somewhere between 30% and 35%, far higher than the usual level of risk, he said. A convergence of forces could destabilize markets, according to Rowan, including a "total geopolitical reset," policies that could prove inflationary by restricting labor and trade, and the sweeping artificial intelligence cycle reshaping jobs and economic growth. "Almost everything we're doing, whether intentional or not, has the potential to be inflationary," Rowan said, an apparent reference to President Donald Trump's tariff and U.S. immigration policies....
Lutnick Testifying Today On Epstein Ties After Dems Demand Subpoena Commerce Secretary Howard Lutnick - a former neighbor and pal of Jeffrey Epstein who emailed the sex offender about visiting his Caribbean island (and then said it was 'nice to see him' in a subsequent email) - will provide closed-door testimony today in front of the US House committee investigating the Epstein's crimes and possib...
Lutnick Testifying Today On Epstein Ties After Dems Demand Subpoena Commerce Secretary Howard Lutnick - a former neighbor and pal of Jeffrey Epstein who emailed the sex offender about visiting his Caribbean island (and then said it was 'nice to see him' in a subsequent email) - will provide closed-door testimony today in front of the US House committee investigating the Epstein's crimes and possible lapses in the law enforcement response. While Lutnick initially claimed he barely knew Epstein (like everybody else), emails and other documents released earlier this year by the DOJ reveals he's full of shit . About That Trip As we noted in February, the trip, planned in 2012, came years after Lutnick claimed he cut all ties with the pedophile . Yet in December of that year, Lutnick sent an email to Epstein saying that he had a group of people, including his wife and children and another family, who were visiting the Caribbean - and inquired as to where Epstein was located and whether they could visit for a meal. Epstein, replying through an assistant, set up a lunch gathering . When reached for comment, Lutnick told the NY Times "I spent zero time with him," before hanging up. The documents suggest the visit did occur. The gathering was set for Dec. 23, 2012. A day later, an assistant to Mr. Epstein forwarded Mr. Lutnick a message from Mr. Epstein: “Nice seeing you,” it said. In a podcast interview last year, Mr. Lutnick claimed that around 2005, he and his wife had been so revolted by Mr. Epstein that they decided not to associate with him again. Mr. Lutnick said in the interview that Mr. Epstein invited them to tour his Upper East Side mansion , next door to Mr. Lutnick’s own home. When they noticed a massage table in the middle of a room, Mr. Lutnick recalled, Mr. Epstein explained that he received “the right kind of massage” every day. Mr. Lutnick said that he and his wife quickly left and decided to “never be in a room with that disgusting person ever again.” Exce...
Bank of America wasted little time in making its view on Palantir (PLTR) clear after another Q1 earnings stunner. The bank maintained its bullish stance on the stock, arguing that Palantir’s AI endeavors are showing up in its sales, margins, contracts, and forward guidance. Palantir has been ...
Bank of America wasted little time in making its view on Palantir (PLTR) clear after another Q1 earnings stunner. The bank maintained its bullish stance on the stock, arguing that Palantir’s AI endeavors are showing up in its sales, margins, contracts, and forward guidance. Palantir has been ...
Flex (NASDAQ:FLEX) used its fiscal fourth-quarter earnings call to outline plans to separate its Cloud and Power Infrastructure (CPI) segment into a new publicly traded company, while also reporting record quarterly margins and issuing a fiscal 2027 outlook that reflects sharply higher capital spend
Flex (NASDAQ:FLEX) used its fiscal fourth-quarter earnings call to outline plans to separate its Cloud and Power Infrastructure (CPI) segment into a new publicly traded company, while also reporting record quarterly margins and issuing a fiscal 2027 outlook that reflects sharply higher capital spend
hapabapa Eli Lilly ( LLY ) will pour another $4.5B to increase capacity at two manufacturing sites in Lebanon, Ind. The company's key type 2 diabetes and weight loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), are manufactured in the city. The three facilities in Lebanon are considered a central part of Lilly's domestic manufacturing capability. The company also intends to have signi...
hapabapa Eli Lilly ( LLY ) will pour another $4.5B to increase capacity at two manufacturing sites in Lebanon, Ind. The company's key type 2 diabetes and weight loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), are manufactured in the city. The three facilities in Lebanon are considered a central part of Lilly's domestic manufacturing capability. The company also intends to have significant production of its recently approved oral GLP-1 Foundayo (orforglipron) done in Lebanon and, subject to approval, retatrutide, another weight loss treatment, currently in phase 3. Since 2020, Lilly has invested $21B in manufacturing in Indiana. More on Eli Lilly Eli Lilly: No Big Gap To Competition Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade) Lilly shares under pressure after serious Foundayo adverse event report Most and least shorted mid-to mega-cap healthcare stocks in May